About oncgnostics GmbH:
oncgnostics GmbH is a spin-off from the university women’s hospital Jena and was founded early in 2012. As a molecular diagnostic company oncgnostics is specialized on cancer diagnostics. Oncgnostics tests target epigenetic changes, so-called DNA methylations, that typically occur in cancer cells. The patented biomarkers which are evaluated using a specific algorithm are the core of the products and provide thus the basis for the company’s activities. Prominent investors have already invested into the market potential of the biotech startup, thus enabling the spin-off of the company and the development of the first product (High-Tech-Gründerfonds, Stiftung für Technologie, Innovation und Forschung Thüringen, bm-t Beteiligungsmanagement Thüringen GmbH and further investors).